Skip to main content
Fascinating to see JAKi uptake in European JAK-pot centres
- tofa was already on the decline pre-ORAL Surveillance
- JAK

David Liew drdavidliew

1 year 3 months ago
Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA
Er

Aurelie Najm AurelieRheumo

1 year 3 months ago
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype It’d be interesting to see if this could predict D2T evolution in early RA pts POS0185 https://t.co/faruOr3HhJ
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Dr. John Cush RheumNow

1 year 3 months ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty
In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease a

Mrinalini Dey DrMiniDey

1 year 3 months ago
In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity. CKD stage ≥3 doubled HCQ levels at same dose. Supports monitoring & dose adjustment in CKD to balance safety & efficacy. @RheumNow #EULAR2025 #OP0199
OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms.
Clinical + US split them into PIPsA vs

Jiha Lee JihaRheum

1 year 3 months ago
OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms. Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t. A step toward smarter care in D2T PsA. @RheumNow #EULAR2025 https://t.co/E9igwvDPPN
New dual-action RA drug?
OP0193: CPL’116 targets both JAK & ROCK.
In 12-wk RCT, highest dose improved DAS28-CRP,

Jiha Lee JihaRheum

1 year 3 months ago
New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow
PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) a

Mrinalini Dey DrMiniDey

1 year 3 months ago
PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE. @RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd
FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis i

Nelly ZIADE 🍀 Nellziade

1 year 3 months ago
FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia ✨️ A promising tool for early diagnosis of PsA Giulia Corte et al. OP#0174 #EULAR2025 @RheumNow https://t.co/QVmoECIhBI
Ph 2 RCT CPL'116 dual inhibition JAK/ROCK
106 MTX IR pts
wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs.

Aurelie Najm AurelieRheumo

1 year 3 months ago
Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM
✨️ New Definition Alert

The GRAPPA definition of
C2M (Complex to Manage)
&
D2T (Difficult to Treat)
#Psoriatic

Nelly ZIADE 🍀 Nellziade

1 year 3 months ago
✨️ New Definition Alert The GRAPPA definition of C2M (Complex to Manage) & D2T (Difficult to Treat) #Psoriatic_arthritis A hope for having a homogeneous and widely accepted definition for future clinical research Presented at #EULAR2025 Proft et al. OP#0175 @RheumNow https://t.co/et9cuMROkb
Combination of LEF and MTX in RA: Yay or Nay?

#EULAR2025 @RheumNow

Aurelie Najm AurelieRheumo

1 year 3 months ago
Combination of LEF and MTX in RA: Yay or Nay? #EULAR2025 @RheumNow
OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all?

In >1,100 RA pts, no link to live

Jiha Lee JihaRheum

1 year 3 months ago
OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025
OP0179: In a psoriasis cohort, 68% of PsA onset sites showed prior subclinical inflammation (26% tender, 32% US+, 42% bo

Jiha Lee JihaRheum

1 year 3 months ago
OP0179: In a psoriasis cohort, 68% of PsA onset sites showed prior subclinical inflammation (26% tender, 32% US+, 42% both). Should we redefine when PsA truly begins? @RheumNow #EULAR2025
ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/

Mrinalini Dey DrMiniDey

1 year 3 months ago
ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/ PPV-23 helped a few but 48% failed to mount robust response. Time to rethink vaccine strategies in RTX-treated patients? @RheumNow #EULAR2025 #OP0173 https://t.co/soU5qfwRib
×